These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

570 related items for PubMed ID: 26719673

  • 1. Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
    Ricchi P, Marsella M.
    Drug Des Devel Ther; 2015; 9():6475-82. PubMed ID: 26719673
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 5. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD007476. PubMed ID: 22336831
    [Abstract] [Full Text] [Related]

  • 6. Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.
    Shirley M, Plosker GL.
    Drugs; 2014 Jun 15; 74(9):1017-27. PubMed ID: 24919862
    [Abstract] [Full Text] [Related]

  • 7. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
    Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD.
    Blood; 2012 Aug 02; 120(5):970-7. PubMed ID: 22589472
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep 02; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 10. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 Sep 02; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Niemeyer C, Bassler D.
    Cochrane Database Syst Rev; 2010 Aug 04; (8):CD007477. PubMed ID: 20687088
    [Abstract] [Full Text] [Related]

  • 13. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan 04; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 14. Deferasirox.
    Stumpf JL.
    Am J Health Syst Pharm; 2007 Mar 15; 64(6):606-16. PubMed ID: 17353569
    [Abstract] [Full Text] [Related]

  • 15. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
    Ho WL, Chung KP, Yang SS, Lu MY, Jou ST, Chang HH, Yang YL, Lin DT, Lin KH.
    J Formos Med Assoc; 2013 Apr 15; 112(4):221-9. PubMed ID: 23537869
    [Abstract] [Full Text] [Related]

  • 16. Deferasirox for transfusion-related iron overload: a clinical review.
    Lindsey WT, Olin BR.
    Clin Ther; 2007 Oct 15; 29(10):2154-66. PubMed ID: 18042472
    [Abstract] [Full Text] [Related]

  • 17. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep 15; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 18. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.
    Eur J Haematol; 2014 Jun 15; 92(6):527-36. PubMed ID: 24580147
    [Abstract] [Full Text] [Related]

  • 19. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
    Gao HY, Li Q, Chen JJ, Chen GF, Li CG.
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul 15; 13(7):531-4. PubMed ID: 21752315
    [Abstract] [Full Text] [Related]

  • 20. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V, Berdousi H, Gotsis E, Kattamis A.
    Br J Haematol; 2010 Dec 15; 151(5):504-8. PubMed ID: 20950401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.